Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Horwitz

Showing results (611-620 of 717) with videos related to

Pageof 72
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 1, 1996
The NIMH Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study: background and methodologyB B Lahey, E W Flagg, H R Bird, et al.
The New England Journal of Medicine|February 5, 2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>Karlo Perica, Nayan Jain, Michael Scordo, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Pageof 72

Showing results (611-620 of 717) with videos related to

Sort By:
Pageof 72
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 1, 1996
The NIMH Methods for the Epidemiology of Child and Adolescent Mental Disorders (MECA) Study: background and methodologyB B Lahey, E W Flagg, H R Bird, et al.
The New England Journal of Medicine|February 5, 2025
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in <i>TP53</i>Karlo Perica, Nayan Jain, Michael Scordo, et al.
American Journal of Hematology|July 12, 2021
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A Lunning, Alison J Moskowitz, et al.
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Pageof 72